期刊
MUSCLE & NERVE
卷 43, 期 5, 页码 700-707出版社
WILEY
DOI: 10.1002/mus.21950
关键词
beta-agonist; clenbuterol; mTOR pathway; muscle growth; myostatin; myostatin prodomain
资金
- USDA-TSTAR [2004-34135-15196]
Introduction: In this study we investigated the combined effect of myostatin (MSTN) suppression and beta-agonist (clenbuterol) administration on muscle hypertrophy and the phosphorylation of muscle 4E-BP1 and p70S6k, two downstream effectors of the Akt/mTOR anabolic pathway. Methods: Female heterozygous MSTN-prodomain transgenic mice (an MSTN suppression model) and wild-type littermates were given 0 or 20 ppm of clenbuterol (CL) in their drinking water, and muscle samples were collected at 1 and 2 weeks after treatment. Results: CL increased body and muscle mass in both genotypes. Levels of phosphorylated muscle 4E-BP1 and p70S6k were higher in MSTN-prodomain transgenic mice than in wildtype mice. CL increased the phosphorylation of 4E-BP1 and p70S6k in both genotypes. Conclusions: The muscle-hypertrophic effect of CL is additive to the effect of MSTN suppression. The combination of MSTN suppression and treatment with beta-agonists may be an effective therapeutic approach to combat muscle-wasting conditions. Muscle Nerve 43: 700-707, 2011
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据